Identification of CGT1263, a Potent KRAS Inhibitor With Selectivity for Mutant KRAS Over HRAS and NRAS – Cogent Biosciences

Skip to content

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

Identification of CGT1263, a Potent KRAS Inhibitor With Selectivity for Mutant KRAS Over HRAS and NRAS

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

File size: 9.89 MB

Created: October 2025

Updated: October 2025

Hits: 30

Download Preview

Cogent Biosciences, Inc.

Massachusetts Office:
275 Wyman Street, 3^rd floor
Waltham, MA 02451

Boulder Office:
4840 Pearl E Circle, Suite 100
Boulder, CO 80301

About
Bezuclastinib
Careers
Pipelines & Research Targets
Patients & Families
Investors & Media
Legal
Privacy Policy
Cookie Notice

Scroll to Top

Scroll to Top